Philip J. Barter

55.9k total citations · 14 hit papers
380 papers, 36.2k citations indexed

About

Philip J. Barter is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cancer Research. According to data from OpenAlex, Philip J. Barter has authored 380 papers receiving a total of 36.2k indexed citations (citations by other indexed papers that have themselves been cited), including 253 papers in Surgery, 222 papers in Endocrinology, Diabetes and Metabolism and 85 papers in Cancer Research. Recurrent topics in Philip J. Barter's work include Diabetes, Cardiovascular Risks, and Lipoproteins (205 papers), Lipoproteins and Cardiovascular Health (195 papers) and Cancer, Lipids, and Metabolism (79 papers). Philip J. Barter is often cited by papers focused on Diabetes, Cardiovascular Risks, and Lipoproteins (205 papers), Lipoproteins and Cardiovascular Health (195 papers) and Cancer, Lipids, and Metabolism (79 papers). Philip J. Barter collaborates with scholars based in Australia, United States and United Kingdom. Philip J. Barter's co-authors include Kerry‐Anne Rye, John J.P. Kastelein, Stephen J. Nicholls, Scott M. Grundy, Jean‐Charles Fruchart, John C. LaRosa, Kerry-Anne Rye, Antonio M. Gotto, Charles L. Shear and Alan R. Tall and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Philip J. Barter

372 papers receiving 35.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease

2005 2.5k citations John C. LaRosa, Philip J. Barter et al. profile →
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

2005 2.4k citations Philip J. Barter, James D. Best et al. The Lancet profile →
Effects of Torcetrapib in Patients at High Risk for Coronary Events

2007 2.2k citations Philip J. Barter, John J.P. Kastelein et al. profile →
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

2012 1.5k citations Anders Olsson, Philip J. Barter et al. profile →
HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events

2007 1.2k citations Philip J. Barter, Antonio M. Gotto et al. profile →
Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity

2020 1.1k citations Robert Ross, Ian J. Neeland et al. Nature Reviews Endocrinology profile →
Antiinflammatory Properties of HDL

2004 1.0k citations Philip J. Barter, Stephen J. Nicholls et al. profile →
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement

2019 917 citations Ian J. Neeland, Robert Ross et al. The Lancet Diabetes & Endocrinology profile →
Cholesteryl Ester Transfer Protein

2003 661 citations Philip J. Barter, Daniel J. Rader et al. Arteriosclerosis Thrombosis and Vascular Biology profile →
High-Density Lipoproteins Inhibit Cytokine-Induced Expression of Endothelial Cell Adhesion Molecules

1995 655 citations Kerry‐Anne Rye, Philip J. Barter et al. Arteriosclerosis Thrombosis and Vascular Biology profile →
Effect of Two Intensive Statin Regimens on Progression of Coronary Disease

2011 644 citations Stephen J. Nicholls, Philip J. Barter et al. profile →
Dysfunctional HDL and atherosclerotic cardiovascular disease

2015 567 citations H. Bryan Brewer, Philip J. Barter et al. profile →
International Day for the Evaluation of Abdominal Obesity (IDEA)

2007 553 citations Jean‐Pierre Després, Philip J. Barter et al. Circulation profile →
Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

2010 544 citations Christopher P. Cannon, Sukrut Shah et al. profile →

Peers

Countries citing papers authored by Philip J. Barter

Since Specialization

Citations

This map shows the geographic impact of Philip J. Barter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip J. Barter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip J. Barter more than expected).

Fields of papers citing papers by Philip J. Barter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip J. Barter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip J. Barter. The network helps show where Philip J. Barter may publish in the future.

Co-authorship network of co-authors of Philip J. Barter

This figure shows the co-authorship network connecting the top 25 collaborators of Philip J. Barter. A scholar is included among the top collaborators of Philip J. Barter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip J. Barter. Philip J. Barter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity breakdown → 2020 ·Nature Reviews Endocrinology ·Robert Ross, Ian J. Neeland, Shizuya Yamashita, Iris Shai, Jacob C. Seidell, Paolo Magni, Raúl D. Santos, Benoît J. Arsenault, Ada Cuevas, Frank B. Hu, Bruce A. Griffin, Alberto Zambon, Philip J. Barter, Jean‐Charles Fruchart, Robert H. Eckel, Yūji Matsuzawa, Jean‐Pierre Després	1094
2	Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement breakdown → 2019 ·The Lancet Diabetes & Endocrinology ·Ian J. Neeland, Robert Ross, Jean‐Pierre Després, Yūji Matsuzawa, Shizuya Yamashita, Iris Shai, Jacob C. Seidell, Paolo Magni, Raúl D. Santos, Benoît J. Arsenault, Ada Cuevas, Frank B. Hu, Bruce A. Griffin, Alberto Zambon, Philip J. Barter, Jean‐Charles Fruchart, Robert H. Eckel	917
3	Association of elevated circulating fibroblast growth factor 21 levels with prevalent and incident metabolic syndrome: The Multi-Ethnic Study of Atherosclerosis 2018 ·Atherosclerosis ·Kwok Leung Ong, Robyn L. McClelland, Matthew Allison, John Kokkinos, Ben J. Wu, Philip J. Barter, Kerry‐Anne Rye	19
4	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East 2016 ·International Journal of Cardiology ·(unknown), Khalid Al‐Rasadi, Fatheya Alawadi, Saeed M G Al-Ghamdi, Wael Al Mahmeed, Fahad Alnouri, (unknown), Zuhier Awan, (unknown), Mohamed Hassanein, Hani Sabbour, Mohammad Zubaid, Philip J. Barter	12
5	Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial 2015 ·The Lancet ·G. Kees Hovingh, John J.P. Kastelein, Sander J. H. van Deventer, Patrick Round, J. Ford, Danish Saleheen, Daniel J. Rader, H. Bryan Brewer, Philip J. Barter	176
6	Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence? 2015 ·Clinical Therapeutics ·Philip J. Barter, Kerry‐Anne Rye	19
7	Predictors of peripheral neuropathy and effects of fenofibrate among 9,795 subjects with type 2 diabetes: the fenofibrate intervention and event lowering in diabetes (FIELD) study 2011 ·Diabetologia ·Anthony Keech, Jaya Rajamani, James D. Best, Graeme J. Hankey, Mark W. Donoghoe, Linda Li, Alicia J. Jenkins, (unknown), Timothy M. E. Davis, Peta Phillips, Philip J. Barter	0
8	Abstract 15035: Effects on Lipids and Safety Following Cessation of Treatment with Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients with or at High Risk for Coronary Heart Disease 2011 ·Circulation ·Antonio M. Gotto, Christopher P. Cannon, Sukrut Shah, Sherry Liu, (unknown), Michael Stepanavage, Eliot A. Brinton, Michael H. Davidson, Hayes M. Dansky, Yale Mitchel, Philip J. Barter	4
9	Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER) 2009 ·The American Journal of Cardiology ·Stephen J. Nicholls, Gunnar Brandrup‐Wognsen, Mike K. Palmer, Philip J. Barter	188
10	Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein 2007 ·Journal of Lipid Research ·Nongnuch Settasatian, Philip J. Barter, Kerry‐Anne Rye	19
11	High-Density Lipoproteins Enhance Progenitor-Mediated Endothelium Repair in Mice 2006 ·Arteriosclerosis Thrombosis and Vascular Biology ·(unknown), (unknown), Wenhua Fan, Campbell Rogers, Kerry‐Anne Rye, Philip J. Barter	150
12	Abstract 3357: Superiority of ApoB/ApoA1 Ratio for Predicting Cardiovascular Risk in Pooled Analyses of the Incremental Decrease in Endpoints through Aggressive Lipid-Lowering (IDEAL) and Treating to New Targets (TNT) Trials 2006 ·Circulation ·John J.P. Kastelein, Ingar Holme, Philip J. Barter, Anders Olsson, Nilo B. Cater, David A. DeMicco, Michael Gaffney, Michael Szarek, John C. LaRosa, Terje R. Pedersen	2
13	Targeting Cholesteryl Ester Transfer Protein for the Prevention and Management of Cardiovascular Disease 2006 ·Journal of the American College of Cardiology ·Philip J. Barter, John J.P. Kastelein	126
14	National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand 2005 ·Heart Lung and Circulation ·Andrew Tonkin, Philip J. Barter, James D. Best, Andrew Boyden, John Furler, (unknown), David Sullivan	55
15	High-density lipoproteins as therapeutic targets 2005 ·Current Opinion in Lipidology ·Stephen J. Nicholls, Kerry-Anne Rye, Philip J. Barter	34
16	Metabolic abnormalities: high-density lipoproteins 2004 ·Endocrinology and Metabolism Clinics of North America ·Philip J. Barter	15
17	Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells 2002 ·Current Opinion in Lipidology ·Philip J. Barter, Paul Baker, Kerry‐Anne Rye	116
18	High-Density Lipoproteins and Coronary Heart Disease 1994 ·European Journal of Cardiovascular Prevention & Rehabilitation ·Philip J. Barter, K.-A. Rye	9
19	Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of myocardial infarction 1988 ·The Lancet ·Peter L. Thompson, Philip E. Aylward, J. Federman, (unknown), (unknown), Nang Latt, A. Pitt, A. G. Thomson, Andrew Tonkin, (unknown), Dallas R. English, Richard Parsons, Konrad Jamrozik, Stefan M. Nidorf, Philip J. Barter, (unknown), R L Blackett, T. Robertson, Jane Neill	222
20	Origin of esterified cholesterol transported in the very low density lipoproteins of human plasma 1974 ·Journal of Lipid Research ·Philip J. Barter	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact